Preferences of healthcare professionals regarding hexavalent pediatric vaccines in Italy: a survey of attitudes and expectations


Healthcare professionals • Hexavalent vaccine • Pediatric vaccination • Pre-filled syringe • Ready-to-use


Introduction. In Italy, three hexavalent pediatric vaccines are available: two are ready-to-use (RTU) as pre-filled syringes, while the third must be reconstituted (need-for-reconstitution [NFR]). The formulation is related to the vaccination timing, safety of preparation and administration, and possible errors in immunization. We surveyed Italian healthcare professionals (HCPs) experienced with RTU and NFR vaccines in order to investigate their opinions on key aspects of the vaccines.

Methods. In Q1 2018, a qualitative study, ethnographic observations and in-depth interviews were performed in public vaccination settings of three Italian Regions. Data on how the vaccination process was managed and perceptions about the value of the RTU formulation were collected. In Q2 2018, face-to-face interviews were carried out to explore the attitude and preferences of Italian HCPs from nine Regions, assessing advantages and disadvantages of the two formulations from a quantitative point of view. In Q3–Q4 data analysis was carried out, using both qualitative and quantitative methodologies.

Results. The first phase demonstrated the following advantages of the RTU versus the NFR formulation: time-saving, lower probability of needle contamination and needle stick incidents, better handling, simpler procedure, easier disposal of waste. For the survey, 149 HCPs were interviewed; 80% and 40%, respectively, were very satisfied with the RTU and NFR vaccine.

Conclusions. Our study demonstrated that HCPs prefer the RTU formulation, as it simplifies vaccinations, reduces preparation time and minimizes the risk of errors. This formulation also saves time that can be spent on more in-depth counseling.


[1] Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, Francia F, Lopalco P, Prato R, Russo R, Villani A, Franco E. Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. J Prev Med Hyg 2018;59:E107-E19.
[2] Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001;20:S10-8. doi: 10.1097/00006454-200111001-00002.
[3] Skibinski DA, Baudner BC, Singh M, O'Hagan DT. Combination vaccines. J Glob Infect Dis 2011;3:63-72. doi: 10.4103/0974-777X.77298.
[4] De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine 2015;33:3976-82. doi: 10.1016/j.vaccine.2015.06.030.
[5] Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: From beliefs to evidence. Hum Vaccin Immunother 2015;11:2132-41. doi: 10.1080/21645515.2015.1044180.
[6] Bozzola E, Spina G, Russo R, Bozzola M, Corsello G, Villani A. Mandatory vaccinations in European countries, undocumented information, false news and the impact on vaccination uptake: the position of the Italian pediatric society. Ital J Pediatr 2018;44:67. doi: 10.1186/s13052-018-0504-y.
[7] World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2019 global summary. Available at: Accessed on 23/03/2020.
[8] European Medicines Agency. Infanrix Hexa. Summary of Product Characteristics. Available at: Accessed on 23/03/2020.
[9] European Medicines Agency. Hexyon. Summary of Product Characteristics. Available at: Accessed on 23/03/2020.
[10] European Medicines Agency. Vaxelis. Summary of Product Characteristics. Available at: Accessed on 23/03/2020.
[11] Petrolini C, Chiappini E, Caffarelli C, Calvani M, Cardinale F, Duse M, Licari A, Manti S, Martelli A, Minasi D, Del Giudice MM, Pajno GB, Pietrasanta C, Pugni L, Tosca M, Mosca F, Marseglia GL. Vaccinazione esavalente nei nati pretermine. Rivista di Immunologia e Allergologia Pediatrica 2019;3-2019:7-23.
[12] Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Vaccine 2016;34:3810-6. doi: 10.1016/j.vaccine.2016.05.054.
[13] Vesikari T, Silfverdal SA, Jordanov E, Feroldi E. A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule. Pediatr Infect Dis J 2017;36:87-93. doi: 10.1097/INF.0000000000001358.
[14] Lloyd AJ, Nafees B, Ziani E, Nicolas L, Fordham BA, Soubeyrand B, Bornhoft C. What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution? Patient Prefer Adherence 2015;9:1517-24. doi: 10.2147/PPA.S87229.
[15] Wiedenmayer KA, Weiss S, Chattopadhyay C, Mukherjee A, Kundu R, Aye R, Tediosi F, Hetzel MW, Tanner M. Simplifying paediatric immunization with a fully liquid DTP-HepB-Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine 2009;27:655-9. doi: 10.1016/j.vaccine.2008.11.045.
[16] Nogier C, Hanlon P, Wiedenmayer K, Maire N. Can a Compact Pre-Filled Auto-Disable Injection System (cPAD) Save Costs for DTP-HepB-Hib Vaccine as Compared with Single-Dose (SDV) and Multi-Dose Vials (MDV)? Evidence from Cambodia, Ghana, and Peru. Drugs Real World Outcomes 2015;2:43-52. doi: 10.1007/s40801-015-0010-0.
[17] Pereira CC, Bishai D. Vaccine presentation in the USA: economics of prefilled syringes versus multidose vials for influenza vaccination. Expert Rev Vaccines 2010;9:1343-9. doi: 10.1586/erv.10.129.
[18] McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim(R)) : a review of its use in primary and booster vaccination. Paediatr Drugs 2013;15:59-70. doi: 10.1007/s40272-013-0007-7.
[19] Gargano LM, Herbert NL, Painter JE, Sales JM, Morfaw C, Rask K, Murray D, DiClemente RJ, Hughes JM. Impact of a physician recommendation and parental immunization attitudes on receipt or intention to receive adolescent vaccines. Hum Vaccin Immunother 2013;9:2627-33. doi: 10.4161/hv.25823.
[20] Ferrara P, Zenzeri L, Fabrizio GC, Gatto A, Pio L, Gargiullo L, Ianniello F, Valentini P, Ranno O. Second-generation immigrant children: health prevention for a new population in terms of vaccination coverage and health assessment. Minerva Pediatr 2016;68:121-6.
[21] Sharp B, Whyte P. New directions in the development of pre-filled syringes. Innov Pharm Technol 2010:64-8. Available at: Accessed on 3/03/2020.